Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study.
Huanyuan Luo, Dorothée Camilleri, Ibon Garitaonandia, Dilshat Djumanov, Tao Chen, Ulrike Lorch, Jörg Täubel, Duolao Wang
Author Information
Huanyuan Luo: Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Dorothée Camilleri: Department of Data Science, Richmond Pharmacology Ltd, London, UK.
Ibon Garitaonandia: Richmond Research Institute, St George's University of London, London, UK.
Dilshat Djumanov: Department of Data Science, Richmond Pharmacology Ltd, London, UK.
Tao Chen: Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Ulrike Lorch: Department of Data Science, Richmond Pharmacology Ltd, London, UK.
Jörg Täubel: Department of Data Science, Richmond Pharmacology Ltd, London, UK; Richmond Research Institute, St George's University of London, London, UK. Electronic address: j.taubel@richmondpharmacology.com.
Duolao Wang: Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. Electronic address: duolao.wang@lstmed.ac.uk.
We aim to study kinetics of anti-SARS-CoV-2 IgG antibody levels in subjects with COVID-19 for up to 11 months and the potential influential factors. The study was a prospective longitudinal study. The analyses were based on 77 serum/plasma samples with a mean of 4 samples per participant (range 1 - 18) in 20 participants with at least one positive Polymerase Chain Reaction testing result from 19 March 2020 up to 10 February 2021. Among the subjects (median age 34.5 years, 65% male), IgG level declined with the follow-up time (per month; geometric mean ratio [GMR] 0.73; 95% CI, 0.72 - 0.74). In a small sample of subjects from the general population with COVID-19, IgG levels declined non-linearly from month 2 to 11 with individual heterogeneity in quantity and changing speed and may be associated with gender, race and the loss of smell and taste.
